Martin is Principal based in the Cambridge office. Martin’s primary area of interest is in biotechnology investment and company creation efforts in a range of therapeutic areas including oncology, cardiovascular, renal and metabolic diseases, and rare disease. Martin joined F-Prime’s London office in 2019, where he has worked on several biotechnology company creation efforts and investments in Europe, including ARTBIO, CHARM Therapeutics and Tenpoint Therapeutics.
Prior to joining F-Prime, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication. Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell, Nature and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.
Brett Cook is a Partner at F-Prime, where he focuses on investments in healthcare technology and service companies. At F-Prime, Brett has led or participated in our investments in Blue Rabbit (acquired by Wedgewood Pharmacy), Iora Health (acquired by One Medical), PatientPing (acquired by Appriss Health), VitalWare (acquired by Health Catalyst), 1up Health, AppliedVR, BenchSci, Better Life Partners, Bluebird Kids Health, Equip, Expressable, NOCD, Paradigm Health, Proximie, Rippl, and Wellbeam, among others. While at F-Prime, and in collaboration with GV and the Broad Institute, Brett also helped launch and run Project Beacon, a social benefit organization that facilitated more than 1.5 million COVID tests for the Commonwealth of Massachusetts and K-12 schools.
Prior to rejoining F-Prime in 2018, Brett led the finance team at PatientPing (acquired by Appriss Health), a healthcare technology company providing real-time admission and discharge notifications to coordinate patient care. Previously, Brett worked at Aledade and McKinsey & Company.
Brett holds an M.B.A. from Harvard Business School and a B.S.E. in Biomedical Engineering from Duke University.
Brian joined F-Prime in 2018 and focuses primarily on investments in the biopharmaceutical and medical technology sectors. Prior to joining F-Prime, Brian was an engagement manager at McKinsey and Company, where he advised pharmaceutical and medical technology companies on business development, R&D, and strategy topics.
Brian holds a PhD in immunology from Yale University and received his B.S. in biochemistry from the University of Notre Dame.
Rachel Feely-Kohl joined F-Prime in January 2018, where she leads the platform team for the tech fund. Prior to F-Prime Rachel spent four years in Chicago supporting community growth and expansion for high-growth companies, including WeWork and Startup Institute. Immediately prior to joining F-Prime, Rachel was the Head of Community for FinTEx Chicago, a FinTech industry association, where she oversaw program development and membership. She began her career working for non-profits, where she helped launched entrepreneurial-focused community programs in the US and abroad.
Rachel received her BA in Government & Politics from the University of Maryland-College Park.
Jay Farber is a Venture Partner at F-Prime, where he leads early-stage investments in FinTech and SaaS companies. Jay joined F-Prime in 2015. He has led or participated in investments in Ashby, Papaya Payments, AvantStay, Quovo, Snapsheet, Vestwell, and System2.
Jay is also General Manager of the technology (GPX) business at Juniper Square, a leading institutional fund administrator and technology provider to VC, PE, and PERE funds. Juniper Square’s clients manage more than $1T in investor capital.
Jay is physically a Bay Area resident and culturally a Seattleite, but has invested across the country and does not hold the Patriots fandom of his F-Prime colleagues against them (mostly).
Ben Gorman is a Principal at F-Prime, where he focuses on early-stage investments in enterprise software and AI. Prior to joining F-Prime, he was a managing consultant at IBM, providing internal strategy and analytics consulting to IBM’s business units and geographies. The primary focus of his work was transforming the company’s go-to-market to better leverage data and ML.
Ben is a graduate of Carnegie Mellon University, where he studied Statistics and Economics. He is an avid mountaineer and has summitted the highest peak on three continents in addition to completing many alpine climbs and ski descents in the mountain west.
Gaurav is a Partner at F-Prime where he focuses on enterprise technology investing. He has led F-Prime investments in Threat Stack (acquired by F5 Networks), RiskRecon (acquired by Mastercard), Protenus (acquired by Bluesight), Risklens (acquired by Safe Security), Lighthouse, Canary Technologies, Funnel, Warmly, Deal Engine, and many others. Prior to F-Prime, Gaurav was a Principal at F-Prime’s sister fund, Eight Roads Ventures Europe, based in London, where he invested in European software and online services businesses and served on the boards of Appsflyer and Neo4j. Previously, Gaurav was a product portfolio manager at EMC’s largest business unit, Symmetrix. Gaurav was a computer scientist by training and spent the early parts of his career at Credit Suisse and McKinsey and Company.
Gaurav attended MIT for his bachelors and masters degrees in computer science, as well as his MBA.
Sanjay Aggarwal is a Venture Partner focused on physical and enterprise AI opportunities. His investments include Seyond (IPO on HKEX), Securonix (acquired by Vista Equity), Mineral Tree (acquired by Global Payments), Snapsheet, MoEngage, Whatfix, Burro, Teleo, Unbox Robotics, and RightHand Robotics. Prior to joining F-Prime, Sanjay was CEO of Unicel Technologies, an India-focused mobile messaging company, which was acquired by Karix Mobile.
Earlier in his career, Sanjay worked at Devonshire Investors (the private equity group of Fidelity Investments), McKinsey and Company in their US and India offices, and at Berkeley Process Control (acquired by Moog Inc), where he built machine automation systems. Sanjay holds a B.S. in Mechanical Engineering from MIT, an M.S. in Mechanical Engineering from UC Berkeley, and an M.B.A. from the MIT Sloan School of Management.
Chong Xu is a Partner at F-Prime. He focuses primarily on biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of AlphaGen Tx, Pediatrix, Skyline Tx, K36 Tx, and RareStone Group. Other companies Chong holds or has held board positions also include OnCusp Tx, Remunix, Shinobi Tx, Sironax, Semma Tx, Adagene, Innovent, etc. Prior to joining F-Prime in 2015, Chong was a management consultant at McKinsey and Company, a hedge fund healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.
Chong holds a PhD in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.
Jessica is a Partner at F-Prime and focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2015, Jessica was an engagement manager in McKinsey and Company’s Boston office, where she focused on pharmaceuticals and medical products and advised companies across a range of strategic, organizational, and operational topics. She began her career at MIT Lincoln Laboratory in the Biodefense Systems group, where she worked on developing novel techniques for the detection of biological agents.
Jessica holds a PhD in genetics from Harvard University and received her BS in biology from Duke University.